Polymeric micelles for targeted tumor therapy of platinum anticancer drugs
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Platinum anticancer drugs are effective against a wide range of tumors, though their severe adverse effects and resistance remain unresolved. A breakthrough in these drawbacks could be achieved by using polymeric micelles, i.e. nanoassemblies having a drug loaded core and a protective hydrophilic shell, incorporating platinum drugs for tumor-targeted delivery. Areas covered: The development of cisplatin- (NC-6004) and DACHPt-loaded micelles (NC-4016) has been reviewed, particularly, from the viewpoint of the effect of their structural features on the tumor-targeting efficacy. We have also described new approaches for molecular targeting by installing ligand moieties on the surface of micelles. Moreover, small platinum drugs and platinum drug-loaded nanocarriers are introduced to explain the context for developing platinum drug-loaded polymeric micelles. Expert opinion: NC-6004 and NC-4016 micelles meet critical structural and functional requirements for achieving safe and effective tumor targeting, enhancing efficacy even against drug resistant cancer cells, and have been translated into human studies, aiming to be the first-of-their-kind in the clinic. Due to their flexible design, polymeric micelles could readily integrate new features based on the knowledge arising from the human clinical trials toward the development of innovative formulations with superior performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“Clinical validation of the liposomal drug delivery strategy was realized with the approval of Doxil, that is, PEGylated liposomes incorporating doxorubicin [37].”
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“Oxaliplatin is used as first-line treatment of advanced colorectal cancer in combination with 5-fluorouracil/ leucovorin [27].”
MethodMolecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Self-citationMaeda, H., Nakamura, H., & Fang, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.10.002 · Cited by 2,376 · cited 1×
“taking advantage of the EPR effect, that is, by exploiting the permeable vasculature and limited lymphatic drainage in cancerous tissues [118].”
BackgroundBae, Y., Fukushima, S., Harada, A., & Kataoka, K. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200250653 · Cited by 1,329
Self-citationNicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., & Couvreur, P. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35265f · Cited by 1,270
Integrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
Shen, D.-W., Pouliot, L. M., Hall, M. D., & Gottesman, M. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.005637 · Cited by 955
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930 · cited 1×
“The specific affinity of antibodies to their target biomolecules has been applied to delivering anticancer drugs to cancer cells, and several antibody-drug conjugates have proceeded into the clinical practice [111].”
Background
Cited by
Metal nanoparticles as a promising technology in targeted cancer treatment
Xu, J.-J., Zhang, W.-C., Guo, Y.-W., Chen, X.-Y., & Zhang, Y.-N. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2039804 · Cited by 276
Qiu, M., Ouyang, J., Sun, H., Meng, F., Cheng, R., Zhang, J., Cheng, L., Lan, Q., Deng, C., & Zhong, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b10533 · Cited by 45
Polymeric micelles and their properties
Wakaskar, R. R. (2017) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000433 · Cited by 44
Bioinspired hyaluronic acid and polyarginine nanoparticles for DACHPt delivery
Matha, K., Lollo, G., Taurino, G., Respaud, R., Marigo, I., Shariati, M., Bussolati, O., Vermeulen, A., Remaut, K., & Benoit, J.-P. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.02.008 · Cited by 35
Metadata
- Authors
- Mochida, Y., Cabral, H., & Kataoka, K.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2017-03-23
- Volume
- 14
- Issue
- 12
- Pages
- 1423-1438
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2599480759
- Cited by
- 64
- References
- 19
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. https://app.cochat.ai/papers/10.1080/17425247.2017.1307338
- The paper
- Mochida, Y., Cabral, H., & Kataoka, K. (2017). Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. Expert Opinion on Drug Delivery. https://doi.org/10.1080/17425247.2017.1307338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.